TTK Healthcare Limited TTKHLTCARE NSEPHARMA
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 10.2% over 5 years.
- Profit CAGR of 25.2% over 5 years.
CONS
- Trading 34.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TTKHLTCARE TTK Healthcare Limited NSEPHARMA | 891.85 | 20.96 | ₹1,260.21 Cr | 1.12% | 10.30% | - | 10.20% | 25.22% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 198.49 Cr | 204.74 Cr | 186.49 Cr | 226.43 Cr | 209.30 Cr |
| Cost of Revenue | 89.85 Cr | 98.03 Cr | 90.41 Cr | 101.82 Cr | 97.62 Cr |
| Gross Profit | 108.64 Cr | 106.71 Cr | 96.09 Cr | 124.61 Cr | 111.68 Cr |
| Operating Expenses | 102.42 Cr | 101.13 Cr | 85.81 Cr | 124.12 Cr | 106.77 Cr |
| Operating Income | 6.22 Cr | 5.58 Cr | 10.27 Cr | 48.75 L | 4.92 Cr |
| EBITDA | 25.93 Cr | 25.53 Cr | 23.45 Cr | 20.61 Cr | 16.99 Cr |
| Interest Expense | 73.83 L | 82.33 L | -47.07 L | 76.96 L | 68.32 L |
| Pretax Income | 23.19 Cr | 22.59 Cr | 21.76 Cr | 17.65 Cr | 14.09 Cr |
| Tax Provision | 5.99 Cr | 5.86 Cr | 5.61 Cr | 4.65 Cr | 3.55 Cr |
| Net Income | 17.20 Cr | 16.73 Cr | 16.15 Cr | 13.00 Cr | 10.53 Cr |
| Diluted EPS | 12.17 | 11.84 | - | 9.20 | 7.45 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 596.07 Cr | 720.19 Cr | 747.64 Cr | 797.63 Cr |
| Cost of Revenue | 287.02 Cr | 350.32 Cr | 340.54 Cr | 371.82 Cr |
| Gross Profit | 309.06 Cr | 369.86 Cr | 407.10 Cr | 425.81 Cr |
| Operating Expenses | 299.59 Cr | 350.77 Cr | 382.11 Cr | 398.88 Cr |
| Operating Income | 9.47 Cr | 19.09 Cr | 24.99 Cr | 26.93 Cr |
| EBITDA | 41.26 Cr | 79.79 Cr | 99.11 Cr | 118.61 Cr |
| Interest Expense | 3.24 Cr | 5.24 Cr | 1.93 Cr | 1.95 Cr |
| Pretax Income | 24.84 Cr | 61.64 Cr | 84.12 Cr | 108.33 Cr |
| Tax Provision | 6.33 Cr | 16.97 Cr | 21.28 Cr | 26.67 Cr |
| Net Income | 41.59 Cr | 639.71 Cr | 62.84 Cr | 81.66 Cr |
| Diluted EPS | 29.43 | 452.72 | 44.47 | 57.79 |
Compounded Sales Growth
| 5 Years: | 10.20% |
| 1 Year: | 2.20% |
Compounded Profit Growth
| 5 Years: | 25.22% |
| 1 Year: | -37.10% |
Stock Price Performance
| 1 Year: | -25.92% |
| 6 Months: | -20.94% |
| 3 Months: | -4.01% |
| 1 Month: | -0.68% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 558.55 Cr | 1,170.11 Cr | 1,206.30 Cr | 1,281.19 Cr |
| Current Assets | 448.51 Cr | 1,066.07 Cr | 1,077.30 Cr | 1,103.89 Cr |
| Cash & Equivalents | 14.86 Cr | 9.32 Cr | 10.96 Cr | 9.01 Cr |
| Inventory | 78.92 Cr | 84.51 Cr | 96.99 Cr | 108.59 Cr |
| Receivables | 53.58 Cr | 92.10 Cr | 86.44 Cr | 90.53 Cr |
| Total Liabilities | 228.92 Cr | 216.73 Cr | 205.38 Cr | 216.14 Cr |
| Current Liabilities | 220.53 Cr | 210.78 Cr | 201.52 Cr | 210.92 Cr |
| Long Term Debt | - | - | - | - |
| Total Debt | 22.21 Cr | 27.33 Cr | 22.81 Cr | 24.22 Cr |
| Total Equity | 329.63 Cr | 953.38 Cr | 1,000.92 Cr | 1,065.05 Cr |
| Shares Outstanding | 1.41 Cr | 1.41 Cr | 1.41 Cr | 1.41 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 45.00 Cr | -24.81 Cr | -4.94 Cr | -3.98 Cr |
| Investing Cash Flow | -29.56 Cr | 31.69 Cr | 28.49 Cr | 20.10 Cr |
| Financing Cash Flow | -10.13 Cr | -12.43 Cr | -21.91 Cr | -18.08 Cr |
| Capital Expenditure | -5.51 Cr | -11.70 Cr | -10.38 Cr | -12.84 Cr |
| Free Cash Flow | 39.49 Cr | -36.51 Cr | -15.33 Cr | -16.82 Cr |
| Net Change in Cash | 5.31 Cr | -5.54 Cr | 1.64 Cr | -1.95 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 51.8% | 51.4% | 54.5% | 53.4% |
| Operating Margin % | 1.6% | 2.7% | 3.3% | 3.4% |
| Net Margin % | 7.0% | 88.8% | 8.4% | 10.2% |
| ROE % | 12.6% | 67.1% | 6.3% | 7.7% |
| ROCE % | 2.8% | 2.0% | 2.5% | 2.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TTKHLTCARE